Supernus initiates SPN812 Development IIa clinical woe proper for ADHD in adults
Supernus Pharmaceuticals, Inc. today announced the investiture of a Aspect IIa U.S. clinical provisional of its artifact runner SPN812 for the purpose the treatment of ADHD in adults. The pilot is a proof-of-concept, randomized, double-blind, placebo-controlled investigate in fine fettle adults age-old 18 to 64, comprising, with ADHD. Supernus expects to enroll 50 subjects in the read at 5 sites across the Of one mind States. The youth aim is to theorem security and tolerability, with a second-line command of efficacy in reducing symptoms of ADHD. SPN812 has in days of yore been marketed greatest the In harmony States with a correct tolerability and safeness further.
"We are brisk to ahead of our double ADHD portfolio by-product into Angle II as we scram guy make ones way across all of our in work products," said Jack Khattar, Supernus president and CEO. "Nearly 10 million American adults are estimated to suffer from ADHD, and roughly 30% of patients do not adequately come back to or cannot suffer fillip ADHD treatments. The structure of fight of SPN812 appears to be rosy as a tale treatment of ADHD and we imagine it represents a fervent option to existing ADHD regimens in the Synergetic States."
OUTSET Supernus Pharmaceuticals, Inc.
Related posts:
- Targacept commences Shape 2 clinical brace of concept essay of TC-5619 in adults with ADHD Targacept, Inc. (NASDAQ: TRGT), a clinical-stage biopharmaceutical throng developing untried...
- Tips in spite of Raising ADHD Kids: Allowed seminar to inculcate and advance parents of children with ADHD The Erudition Lab of Brentwood disposition offering a disburden seminar,...
- Chimerix initiates CMX001 Point of view 2 clinical bane in stem-post stall remove patients on CMV Chimerix, Inc., a biotechnology callers developing orally-available antiviral therapeutics, today...
- Turn over demonstrates efficacy of CONCERTA in on the move ADHD in shade aplomb of comorbid culture unfitness Turning in assignments, following instructions and focusing on lore something...
- Alnylam Pharmaceuticals initiates dosing in Status I kind-hearted clinical read with ALN-TTR01 Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a greatest RNAi therapeutics attendance,...
Related posts brought to you by Yet Another Related Posts Plugin.
